Pea (Pisum sativum L.) seed albumin extracts show anti-inflammatory effect in the DSS model of mouse colitis

Molecular Nutrition and Food Research

Volumn 59, Issue 4, 2015, Pages 807-819

  Utrilla, M Pilar ^a   Peinado, M Jesus ^b   Ruiz, Raquel ^b   Rodriguez Nogales, Alba ^a   Algieri, Francesca ^a   Rodriguez Cabezas, M Elena ^a   Clemente, Alfonso ^b   Galvez, Julio ^a   Rubio, Luis A ^b  

^a UNIVERSITY OF GRANADA   (Spain)

^b CSIC   (Spain)

Author keywords

Bowman Birk inhibitor; Intestinal microbiota; Mouse DSS experimental colitis; Pea protein fractions; Pisum sativum

Indexed keywords

BACTERIA (MICROORGANISMS); MUS; PISUM SATIVUM;

ALBUMINOID; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2; DEXTRAN SULFATE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; PTGS2 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR;

ANIMAL; C57BL MOUSE; CECUM; CHEMICALLY INDUCED; CHEMISTRY; COLITIS; COLON; DISEASE MODEL; DRUG EFFECTS; GENETICS; INTESTINE; INTESTINE FLORA; MALE; METABOLISM; MICROBIOLOGY; MOUSE; PEA; PLANT SEED;

ALBUMINS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CECUM; COLITIS; COLON; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTESTINES; MALE; MICE; MICE, INBRED C57BL; PEAS; RNA, MESSENGER; SEEDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84926104156     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400630     Document Type: Article

References (70)

1. Xavier, R. J. Podolsky, D. K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448, 427-434.
2. Ng, S. C. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract. Res. Clin. Gastroenterol. 2014, 28, 363-372.
3. Gentschew, L. Ferguson, L. R. Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol. Nutr. Food Res. 2012, 56, 524-535.
4. Lakatos, P. L. Environmental factors affecting inflammatory bowel disease: have we made progress? Dig. Dis. 2009, 27, 215-225.
5. Jantchou, P. Morois, S. Clavel-Chapelon, F. Boutron-Ruault, M. C. et al. Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study. Am. J. Gastroenterol. 2010, 105, 2195-2201.
6. Hou, J. K. Abraham, B. El-Serag, H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am. J. Gastroenterol. 2011, 106, 563-573.
7. Siegel, C. A. Review article: explaining risks of inflammatory bowel disease therapy to patients. Aliment. Pharmacol. Ther. 2011, 33, 23-32.
8. Jowett, S. L. Seal, C. J. Pearce, M. S. Phillips, E. et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut 2004, 53, 1479-1484.
9. Viladomiu, M. Hontecillas, R. Yuan, L. Lu, P. et al. et al. Nutritional protective mechanisms against gut inflammation. J. Nutr. Biochem. 2013, 24, 929-939.
10. Morgan, X. C. Tickle, T. L. Sokol, H. Gevers, D. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012, 13, R79.
11. Mitsuyama, K. Sata, M. Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease. Expert Opin. Ther. Targets 2008, 12, 301-312.
12. Frank, D. N. St Amand, A. L. Feldman, R. A. Boedeker, E. C. et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. USA 2007, 104, 13780-13785.
13. Damaskos, D. Kolios, G. Probiotics and prebiotics in inflammatory bowel disease: microflora "on the scope." Br. J. Clin. Pharmacol. 2008, 65, 453-467.
14. Dicksved, J. Schreiber, O. Willing, B. Petersson, J. et al. Lactobacillus reuteri maintains a functional mucosal barrier during DSS treatment despite mucus layer dysfunction. Plos One 2012, 7, e46399.
15. Lupp, C. Robertson, M. L. Wickham, M. E. Sekirov, I. et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2, 119-129.
16. Verma, N. Verma, R. Kumari, R. Ranjha, R. et al. Effect of salicin on gut inflammation and on selected groups of gut microbiota in dextran sodium sulfate induced mouse model of colitis. Inflamm. Res. 2014, 63, 161-169.
17. Sartor, R. B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134, 577-594.
18. Cabré, E. Domènech, E. Impact of environmental and dietary factors on the course of inflammatory bowel disease. World J. Gastroenterol. 2012, 18, 3814-3822.
19. Hartman, C. Eliakim, R. Shamir, R. Nutritional status and nutritional therapy in inflammatory bowel diseases. World J. Gastroenterol. 2009, 15, 2570-2578.
20. Griffiths, A. M. Enteral nutrition in the management of Crohn's disease. J. Parenter. Enteral Nutr. 2004, 29(4 Suppl), S108-S112.
21. Clemente, A. Domoney, C. Biological significance of polymorphism in legume protease inhibitors from the Bowman-Birk family. Curr. Protein Pept. Sci. 2006, 7, 201-216.
22. Clemente, A. Jimenez, E. Marín-Manzano, M. C. Rubio, L. A. Active Bowman-Birk inhibitors survive gastrointestinal digestion at the terminal ileum of pigs fed chickpea-based diets. J. Sci. Food Agric. 2008, 88, 523-531.
23. Clemente, A. Sonnante, G. Domoney, C. Bowman-Birk inhibitors from legumes and human gastrointestinal health: current status and perspectives. Curr. Prot. Pept. Sci. 2011, 12, 358-373
24. Clemente, A. Marín-Manzano, M. C. Jiménez, E. Arques, M. C. et al. The anti-proliferative effect of TI1B, a major Bowman-Birk isoinhibitor from pea (Pisum sativum L.), on HT29 colon cancer cells is mediated through protease inhibition. Br. J. Nutr. 2012, 108 (Suppl 1), S135-S144.
25. Clemente, A. Arques, M. C. Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents. World J. Gastroenterol. 2014, 20, 10305-10315.
26. Ware, J. H. Wan, X. S. Newberne, P. Kennedy, A. R. Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Dig. Dis. Sci. 1999, 44, 986-990.
27. Lichtenstein, G. R. Deren, J. J. Katz, S. Lewis, J. D. et al. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig. Dis. Sci. 2008, 53, 175-180.
28. Ware, J. H. Wan, X. S. Rubin, H. Schechter, N. M. et al. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch. Biochem. Biophys. 1997, 344, 133-138.
29. Clemente, A. Gee, J. M. Johnson, I. T. MacKenzie, D. A. et al. Pea (Pisum sativum L.) protease inhibitors from the Bowman-Birk class influence the growth of human colorectal adenocarcinoma HT29 cells in vitro. J. Agric. Food Chem. 2005, 53, 8979-8986.
30. Rubio, L. A. Pérez, A. Ruiz, R. Guzmán, M. A. et al. Characterization of pea (Pisum sativum) seed protein fractions. J. Sci. Food Agric. 2014, 94, 280-287.
31. Garrido-Mesa, N. Camuesco, D. Arribas, B. Comalada, M. Bailón, E. et al. The intestinal anti-inflammatory effect of minocycline in experimental colitis involves both its immunomodulatory and antimicrobial properties. Pharmacol. Res. 2011, 63, 308-319.
32. Arques, M. C. Marín-Manzano, M. C. Clarissa-Brito, L. Hernandez-Ledesma, B. et al. Quantitative determination of active Bowman-Birk isoinhibitors, IBB1 and IBBD2, in commercial soymilks. Food Chem. 2014, 155, 24-30.
33. Camuesco, D. Comalada, M. Rodríguez-Cabezas, M. E. Nieto, A. et al. The intestinal anti-inflammatory effect of quercitrin is associated with an inhibition in iNOS expression. Br. J. Pharmacol. 2004, 143, 908-918.
34. Camuesco, D. Rodríguez-Cabezas, M. E. Garrido-Mesa, N. Cueto-Sola, M. et al. The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br. J. Pharmacol. 2012, 165, 729-740.
35. Marín-Manzano, M. C. Ruiz, R. Jiménez, E. Rubio, L. A. et al. Bowman-Birk inhibitors from soybean survive fermentation in active form using swine faecal inoculum and do not affect the microbiota composition. Br. J. Nutr. 2009, 101, 967-971.
36. Valatas, V. Vakas, M. Kolios, G. The value of experimental models of colitis in predicting efficacy of biological therapies for inflammatory bowel diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 305, G763-G785.
37. Yan, Y. Kolachala, V. Dalmasso, G. Nguyen, H. et al. Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS ONE 2009, 4, e6073.
38. Taylor, C. T. Dzus, A. L. Colgan, S. P. Autocrine regulation of epithelial permeability by hypoxia: role for polarized release of tumor necrosis factor alpha. Gastroenterology 1998114 657-668.
39. Wirtz, S. Neufert, C. Weigmann, B. Neurath, M. F. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2007, 2, 541-546.
40. Jacob, C. Yang, P. C. Darmoul, D. Amadesi, S. et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and beta-arrestins. J. Biol. Chem. 2005, 280, 31936-3148.
41. Nagalingam, N. A. Kao, J. Y. Young, V. B. Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis. Inflamm. Bowel Dis. 2011, 17, 917-926.
42. Håkansson, A. Tormo-Badia, N. Baridi, A. Xu, J. et al. Immunological alteration and changes of gut microbiota after dextran sulfate sodium (DSS) administration in mice. Clin. Exp. Med. 2015, 15, 107-120.
43. Cader, M. Z. Kaser, A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013, 62, 1653-1664.
44. Hou, J. H. Abraham, B. El-Serag, H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am. J. Gastroenterol. 2011, 106, 563-573.
45. Montonen, J. Boeing, H. Fritsche, A. Schleicher, E. et al. Consumption of red meat and whole-grain bread in relation to biomarkers of obesity, inflammation, glucose metabolism and oxidative stress. Eur. J. Nutr. 2013, 52, 337-345.
46. Natividad E. M. M. Verdu, L. F. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharm. Res. 2013, 63, 42-51.
47. Furuse, M. Itoh, M. Hirase, T. Nagafuchi, A. et al. Direct association of occludin with ZO-1 and its possible involvement in the localization of occludin at tight junctions. J. Cell Biol. 1994, 127, 1617-1626.
48. Kim, Y. S. Ho, S. B. Intestinal goblet cells and mucins in health and disease: recent insights and progress. Curr. Gastroenterol. Rep. 2010, 12, 319-330.
49. Gersemann, M. Becker, S. Kübler, I. Koslowski, M. et al. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 2009, 77, 84-94.
50. Mankertz, J. Schulzke, J. D. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr. Opin. Gastroenterol. 2007, 23, 379-383.
51. Su, L. Shen, L. Clayburgh, D. R. Nalle, S. C. et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009, 136, 551-563.
52. Jiang, H. Przybyszewski, J. Mitra, D. Becker, C. et al. Soy protein diet, but not Lactobacillus rhamnosus GG, decreases mucin-1, trefoil factor-3, and tumor necrosis factor-α in colon of dextran sodium sulfate-treated C57BL/6 mice. J. Nutr. 2011, 141, 1239-1246.
53. Gran, B. Tabibzadeh, N. Martin, A. Ventura, E. S. et al. The protease inhibitor, Bowman-Birk inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis. Mult. Scler. 2006, 12, 688-697.
54. Safavi, F. Rostami, A. Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases. Exp. Mol. Pathol. 2012, 93, 428-433.
55. Róka, R. Rosztóczy, A. Leveque, M. Izbéki, F. et al. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 2007, 5, 550-555.
56. Gecse, K. Róka, R. Ferrier, L. Leveque, M. et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008, 57, 591-599.
57. Motta, J. P. Magne, L. Descamps, D. Rolland, C. et al. Modifying the protease, antiprotease pattern by elafin overexpression protects mice from colitis. Gastroenterology 2011, 140, 1272-1282.
58. Schmid, M. Fellermann, K. Fritz, P. Wiedow, O. et al. Attenuated induction of epithelial and leukocyte serine antiproteases elafin and secretory leukocyte protease inhibitor in Crohn's disease. J. Leukoc. Biol. 2007, 81, 907-915.
59. Meijer, M. J. Mieremet-Ooms, M. A. vander Zon, A. M. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig. Liver Dis. 2007, 39, 733-739.
60. Ravi, A. Garg, P. Sitaraman, S. V. Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm. Bowel Dis. 2007, 13, 97-107.
61. Parks, W. C. Wilson, C. L. López-Boado, Y. S. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 2004, 4, 617-629.
62. Naito, Y. Yoshikawa, T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol. Aspects Med. 2005, 26, 379-390.
63. Esposito, E. Mazzon, E. Riccardi, L. Caminiti, R. et al. Matrix metalloproteinase-9 and metalloproteinase-2 activity and expression is reduced by melatonin during experimental colitis. J. Pineal Res. 2008, 45, 166-173.
64. Walsh, D. McCarthy, J. O'Driscoll, C. Melgar, S. Pattern recognition receptors-molecular orchestrators of inflammation in inflammatory bowel disease. Cytokine Growth Factor Rev. 2013, 24, 91-104.
65. Zheng, B. Morgan, M. E. vande Kant, H. J. Garssen, J. et al. Transcriptional modulation of pattern recognition receptors in acute colitis in mice. Biochim. Biophys. Acta 2013, 1832, 2162-2172.
66. Rakoff-Nahoum, S. Medzhitov, R. Toll-like receptors and cancer. Nat. Rev. Cancer 2009, 9, 57-63.
67. Abraham, C. Medzhitov, R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology 2011, 140, 1729-1737.
68. Hart, A. L. Al-Hassi, H. O. Rigby, R. J. Bell, S. J. et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 2005, 129, 50-65.
69. Marín-Manzano, M. C. Abecia, L. Hernández-Hernández, O. Sanz, M. L. et al. Structural characteristics of galacto-oligosaccharides affect their bifidogenic properties on the intestinal microbiota of rats. J. Agric. Food Chem. 2013, 61, 7560-7567.
70. Flint, H. J. Scott, K. P. Duncan, S. H. Louis, P. et al. Microbial degradation of complex carbohydrates in the gut. Gut Microbes 2012, 3, 289-306.